STING modulators: Predictive significance in drug discovery

European Journal of Medicinal Chemistry
2019.0

Abstract

Cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) - stimulator of interferon genes (STING) signaling pathway plays the critical role in the immune response to DNA. Pharmacological modulation of the STING pathway has been well characterized both from structural and functional perspectives, which paves the way for the drug design of small modulators by medicinal chemists. Here, we outline recent progress in studies on the STING pathway, the structure and biological function of STING, the STING related disease, as well as the rationale and progress in the development of STING modulators. Our review demonstrates that STING is a promising drug target, and providing clues for the discovery of novel STING agonists and antagonists for the potential treatment of various disease including microbial infectious diseases, cancer, and autoimmune disease.

Knowledge Graph

Similar Paper

STING modulators: Predictive significance in drug discovery
European Journal of Medicinal Chemistry 2019.0
Small molecules targeting cGAS-STING pathway for autoimmune disease
European Journal of Medicinal Chemistry 2022.0
Enzymatic Preparation of 2′–5′,3′–5′-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations
Journal of Medicinal Chemistry 2019.0
Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin
Bioorganic & Medicinal Chemistry 2022.0
Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications
Journal of Medicinal Chemistry 2019.0
Modulators of the Sphingosine 1-phosphate receptor 1
Bioorganic & Medicinal Chemistry Letters 2013.0
Targeting the homologous recombination pathway by small molecule modulators
Bioorganic & Medicinal Chemistry Letters 2014.0
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis
Bioorganic & Medicinal Chemistry 2017.0
Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases
European Journal of Medicinal Chemistry 2020.0
Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): Targeting cytokines and cytokine receptor complexes
Bioorganic & Medicinal Chemistry Letters 2021.0